IGC PHARMA INC (IGC) Fundamental Analysis & Valuation

NYSEARCA:IGC • US45408X3089

Current stock price

0.351 USD
+0.03 (+10.17%)
At close:
0.35 USD
0 (-0.28%)
After Hours:

This IGC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IGC Profitability Analysis

1.1 Basic Checks

  • IGC had negative earnings in the past year.
  • In the past year IGC has reported a negative cash flow from operations.
  • In the past 5 years IGC always reported negative net income.
  • In the past 5 years IGC always reported negative operating cash flow.
IGC Yearly Net Income VS EBIT VS OCF VS FCFIGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • IGC has a Return On Assets of -61.24%. This is in the lower half of the industry: IGC underperforms 71.73% of its industry peers.
  • With a Return On Equity value of -73.74%, IGC is not doing good in the industry: 60.73% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -61.24%
ROE -73.74%
ROIC N/A
ROA(3y)-93.23%
ROA(5y)-72.05%
ROE(3y)-122.42%
ROE(5y)-91.4%
ROIC(3y)N/A
ROIC(5y)N/A
IGC Yearly ROA, ROE, ROICIGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • IGC's Gross Margin of 37.36% is in line compared to the rest of the industry. IGC outperforms 59.69% of its industry peers.
  • IGC's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for IGC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.84%
GM growth 5Y75.22%
IGC Yearly Profit, Operating, Gross MarginsIGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. IGC Health Analysis

2.1 Basic Checks

  • IGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IGC has more shares outstanding
  • The number of shares outstanding for IGC has been increased compared to 5 years ago.
  • Compared to 1 year ago, IGC has a worse debt to assets ratio.
IGC Yearly Shares OutstandingIGC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IGC Yearly Total Debt VS Total AssetsIGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • IGC has an Altman-Z score of -10.33. This is a bad value and indicates that IGC is not financially healthy and even has some risk of bankruptcy.
  • IGC has a Altman-Z score of -10.33. This is in the lower half of the industry: IGC underperforms 75.92% of its industry peers.
  • IGC has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.02, IGC perfoms like the industry average, outperforming 53.40% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -10.33
ROIC/WACCN/A
WACC9.49%
IGC Yearly LT Debt VS Equity VS FCFIGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M

2.3 Liquidity

  • IGC has a Current Ratio of 1.32. This is a normal value and indicates that IGC is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.32, IGC is doing worse than 79.06% of the companies in the same industry.
  • IGC has a Quick Ratio of 1.32. This is a bad value and indicates that IGC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.89, IGC is doing worse than 81.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.89
IGC Yearly Current Assets VS Current LiabilitesIGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. IGC Growth Analysis

3.1 Past

  • IGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.65%, which is quite good.
  • Looking at the last year, IGC shows a very negative growth in Revenue. The Revenue has decreased by -20.12% in the last year.
  • IGC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.77% yearly.
EPS 1Y (TTM)16.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.15%
Revenue 1Y (TTM)-20.12%
Revenue growth 3Y47.02%
Revenue growth 5Y-20.77%
Sales Q2Q%-53.64%

3.2 Future

  • IGC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.25% yearly.
  • Based on estimates for the next years, IGC will show a small growth in Revenue. The Revenue will grow by 0.24% on average per year.
EPS Next Y7.95%
EPS Next 2Y3.25%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-11.13%
Revenue Next 2Y0.24%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IGC Yearly Revenue VS EstimatesIGC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
IGC Yearly EPS VS EstimatesIGC Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.05 -0.1 -0.15 -0.2

More info and screens

Find the best growth stocksShow best growing peers

0

4. IGC Valuation Analysis

4.1 Price/Earnings Ratio

  • IGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IGC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IGC Price Earnings VS Forward Price EarningsIGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IGC Per share dataIGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.25%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IGC Dividend Analysis

5.1 Amount

  • No dividends for IGC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IGC Fundamentals: All Metrics, Ratios and Statistics

IGC PHARMA INC

NYSEARCA:IGC (4/22/2026, 8:04:00 PM)

After market: 0.35 0 (-0.28%)

0.351

+0.03 (+10.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-02
Earnings (Next)06-25
Inst Owners20.11%
Inst Owner Change0.21%
Ins Owners3.92%
Ins Owner Change5.39%
Market Cap32.60M
Revenue(TTM)1.06M
Net Income(TTM)-5.97M
Analysts80
Price Target4.08 (1062.39%)
Short Float %0.87%
Short Ratio2.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.54%
Min Revenue beat(2)-26.7%
Max Revenue beat(2)-0.38%
Revenue beat(4)2
Avg Revenue beat(4)-4.75%
Min Revenue beat(4)-26.7%
Max Revenue beat(4)7.13%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.34%
PT rev (3m)10.34%
EPS NQ rev (1m)4.38%
EPS NQ rev (3m)-30.41%
EPS NY rev (1m)-4.72%
EPS NY rev (3m)-31.84%
Revenue NQ rev (1m)-20.31%
Revenue NQ rev (3m)-20.31%
Revenue NY rev (1m)-15.05%
Revenue NY rev (3m)-15.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.75
P/FCF N/A
P/OCF N/A
P/B 4.03
P/tB 10.15
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.01
BVpS0.09
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -61.24%
ROE -73.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.36%
FCFM N/A
ROA(3y)-93.23%
ROA(5y)-72.05%
ROE(3y)-122.42%
ROE(5y)-91.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.84%
GM growth 5Y75.22%
F-Score3
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 220.99%
Cap/Sales 92.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 0.89
Altman-Z -10.33
F-Score3
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)84.26%
Cap/Depr(5y)139.57%
Cap/Sales(3y)48.11%
Cap/Sales(5y)101.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.15%
EPS Next Y7.95%
EPS Next 2Y3.25%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-20.12%
Revenue growth 3Y47.02%
Revenue growth 5Y-20.77%
Sales Q2Q%-53.64%
Revenue Next Year-11.13%
Revenue Next 2Y0.24%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-57.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-49.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.44%
OCF growth 3YN/A
OCF growth 5YN/A

IGC PHARMA INC / IGC Fundamental Analysis FAQ

What is the fundamental rating for IGC stock?

ChartMill assigns a fundamental rating of 1 / 10 to IGC.


What is the valuation status of IGC PHARMA INC (IGC) stock?

ChartMill assigns a valuation rating of 0 / 10 to IGC PHARMA INC (IGC). This can be considered as Overvalued.


What is the profitability of IGC stock?

IGC PHARMA INC (IGC) has a profitability rating of 1 / 10.


What is the earnings growth outlook for IGC PHARMA INC?

The Earnings per Share (EPS) of IGC PHARMA INC (IGC) is expected to grow by 7.95% in the next year.